Trial Profile
Phase II Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jan 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 13 Dec 2022 Results identifying robust predictors for Ibrutinib response by multi omic genomics in MYD88 mutated Waldenstroms Macroglobulinemia, presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 05 Dec 2022 Status changed from active, no longer recruiting to completed.
- 12 Sep 2022 Planned End Date changed from 1 Feb 2023 to 1 Oct 2022.